ASRT Share Price Performance
US$18.04
8.73 (93.85%)
15.4% undervalued intrinsic discount
US$21.33
Fair Value
Price US$18.04
AnalystConsensusTarget US$21.33
AnalystLowTarget US$28.00
AnalystHighTarget US$45.00
Fair ValueUS$21.33
Share Pricen/a
Assertio Holdings, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 32 Fair Values set on narratives written by author
ASRT Community Narratives
AN
Fair Value
·Fair Value US$21.33 15.4% undervalued intrinsic discount
Rolvedon And Sympazan Will Open New Healthcare Frontiers
0users have liked this narrative
0users have commented on this narrative
17users have followed this narrative
AN
Fair Value
·Fair Value US$28 35.6% undervalued intrinsic discount
Rising Pricing Pressures And Portfolio Exposure Will Test Future Recoveries
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value
·Fair Value US$45 59.9% undervalued intrinsic discount
Digital Health And Non-Opioid Therapies Will Transform Pain Management
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Rolvedon And Sympazan Will Open New Healthcare Frontiers
Key Takeaways Expanding key products and broader payer agreements drive sustainable revenue growth, while a digital-first model and divestitures improve operational efficiency and margins. Strong cash reserves and reduced legal liabilities enable strategic acquisitions, supporting industry consolidation, diversification, and long-term profitability.Read more
AN
US$21.33
15.4% undervalued intrinsic discount
Fair Value
Profit Margin
10.85%
Future PE
14.04x
Price in 2029
US$23.64
Rising Pricing Pressures And Portfolio Exposure Will Test Future Recoveries
Key Takeaways Heavy dependence on a concentrated drug portfolio and mounting pricing pressures create major risks to future revenue stability and profitability. Regulatory scrutiny, generic competition, and shifting payer policies threaten Assertio's ability to offset margin pressure despite operational improvements and acquisition potential.Read more
AN
US$28
35.6% undervalued intrinsic discount
Fair Value
Profit Margin
30.33%
Future PE
4.54x
Price in 2029
US$31.03
Digital Health And Non-Opioid Therapies Will Transform Pain Management
Key Takeaways Assertio is poised for significant revenue and margin expansion through rapid operational improvements, robust product demand, and strategic divestitures. Strong positioning in non-opioid pain and specialty pharmaceuticals, coupled with disciplined portfolio expansion, sets up Assertio for accelerated long-term growth.Read more
AN
US$45
59.9% undervalued intrinsic discount
Fair Value
Profit Margin
15.79%
Future PE
15.54x
Price in 2029
US$50.76
Trending Discussion
Recently Updated Narratives
AN
ASRT: Takeover Agreement Will Support Earnings Power And Rerating Potential
Fair Value: US$21.33 15.4% undervalued intrinsic discount
17 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
ASRT: Reverse Split And 2026 Guidance Will Shape Future Upside Potential
Fair Value: US$28 35.6% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
ASRT: Cost Discipline And 15% Margins Will Support Future Upside Potential
Fair Value: US$45 59.9% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Assertio Holdings, Inc. Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- -4.71
- 70.19%
- -25.59%
- 41.6%
About ASRT
- Founded
- 2020
- Employees
- 53
- CEO
- WebsiteView website
Assertio Holdings, Inc., a pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.
